Abstract: Compounds of the general formula (I) and compounds of the general formula (II) Use of compounds (I) or (II) as visible or invisible markers, for staining materials, in the laser welding of materials, for detecting bases, acids or pH changes, as a dispersing assistant, pigment additive for organic pigments and intermediates for the production of pigment additives, in heat management or energy management, in photovoltaics or in optical data storage.

Abstract: The present invention relates to liquid-crystalline rylenetetracarboxylic acid derivatives, to processes for their preparation and to their use as n-type organic semiconductors for producing organic field-effect transistors and solar cells.

Abstract: The current invention relates to a perylene-3,4-dicarboxylic anhydride, substituted in the 9-position, of the general formula III wherein Z is bromine or cyano, and processes for preparing 9-bromoperylene-3,4-dicarboxylic anhydride and 9-cyanoperylene-3,4-dicarboxylic anhydride.

Abstract: The invention relates to aqueous primary dispersions which contain a hydrophobic polyurethane which is produced in a mini-emulsion by reacting with (a) polyisocyanate and (b) compounds containing isocyanate reactive groups. The invention also relates to a method for producing said dispersion and the use thereof for producing coatings and adhesives.

Abstract: A process for producing aqueous primary dispersions of polymer-ensheathed pigment, which comprises (a) at least one polyfunctional isocyanate and (b) at least one compound having isocyanate-reactive groups selected from polyetherols, polyesterols, polyhydric alcohols having up to 8 carbon atoms, polycarbonate diols, polyhydroxyolefins, polyhydroxyurethanes, polyisobutenediols, polysiloxanes having on average at least 2 hydroxyl groups per molecule and lactone-based polyesterdiols being mixed with pigment, water and if appropriate one or more surface-active substances and reacted with each other.

Abstract: The present inventions relates to substances which are capable of controlling the inclusion of exon (10) of the tau gene. The substances can reverse “wrong” tau splicing pattern and. Since “wrong” tau splicing patterns are associated with tauopathies that cause dementia, the substances can be used as therapeutic agents. The invention also provides a method for testing substances that control tau exon (10) inclusion. The method is suitable for a high throughput screening. Additional products which are useful for changing tau exon (10) expression or for performing the test method are described as well.